Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161080 | 0.84 | LIPG (0.40) | — | |
| SCHEMBL20161027 | 0.84 | KDM4E (0.46) | KDM4EGLAATML3MBTL1MGAM | |
| SCHEMBL15451817 | 0.82 | KDM4E (0.42) | AHRKDM4EATML3MBTL1TNKS | |
| SCHEMBL17245952 | 0.82 | KDM4E (0.46) | AHRCA1CA2KDM4EATM | |
| SCHEMBL15681167 | 0.82 | MAOA (0.36) | AHRKDM4EATML3MBTL1TNKS | |
| SCHEMBL22143454 | 0.81 | RXFP1 (0.33) | MAPT | |
| SCHEMBL17245964 | 0.80 | KDM4E (0.44) | AHRCA1CA2KDM4EATM | |
| SCHEMBL24174411 | 0.80 | KDM4E (0.44) | AHRKDM4EGLAATML3MBTL1 | |
| SCHEMBL24676476 | 0.80 | KDM4E (0.44) | AHRKDM4EGLAATML3MBTL1 | |
| SCHEMBL24676177 | 0.80 | KDM4E (0.44) | AHRKDM4EGLAATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230354701-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230354701-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4271163-A2 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | Merck Patent GmbH (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-11711976-B2 | Compounds with an acceptor and a donor group | MERCK PATENT GMBH (DE) | 2023-07-25 | — | — | US | disclosed |
| US-11711976-B2 | Compounds with an acceptor and a donor group | MERCK PATENT GMBH (DE) | 2023-07-25 | — | — | US | disclosed |
| US-20200203624-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | US | disclosed |
| WO-2018087346-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | MERCK PATENT GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11711976-B2 | Compounds with an acceptor and a donor group | NQO1, ICMT, NUDT1 | AHR 1578/4885CA1 4761/4885CA2 4739/4885 |
| US-20200203624-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | NQO1, ICMT, NUDT1 | AHR 1578/4885CA1 4761/4885CA2 4739/4885 |
| US-20230354701-A1 | COMPOUNDS WITH AN ACCEPTOR AND A DONOR GROUP | NQO1, ICMT, NUDT1 | AHR 1578/4885CA1 4761/4885CA2 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.